Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 746964105 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
Orbimed Advisors LLC
13D/A
|
13.9% |
7/20/2026
Event 7/16/2026
|
||
| Orbimed Advisors LLC | 13.9% | |||
| Orbimed Capital GP VII LLC | 11.8% | |||
| OrbiMed Genesis GP LLC | 2.1% | |||
|
Boxer Capital Management, LLC
13G
|
13.3% |
7/10/2026
Event 6/30/2026
|
||
| Boxer Capital Management, LLC | 13.3% | |||
| Boxer Holdings, LP | 13.3% | |||
| Boxer Holdings GP, LLC | 13.3% | |||
| Aaron Davis | 13.3% | |||
|
Biotechnology Value Fund L P
13G
|
10.0% |
6/4/2026
Event 5/28/2026
|
||
| Biotechnology Value Fund L P | 5.3% | |||
| BVF I GP LLC | 5.3% | |||
| Biotechnology Value Fund II LP | 3.9% | |||
| BVF II GP LLC | 3.9% | |||
| Biotechnology Value Trading Fund OS LP | 0.7% | |||
| BVF Partners OS Ltd. | 0.7% | |||
| BVF GP Holdings LLC | 9.2% | |||
| BVF Partners L P/IL | 10.0% | |||
| BVF Inc/IL | 10.0% | |||
| Lampert Mark N | 10.0% | |||
|
RA Capital Management, L.P.
13G
|
9.8% |
6/4/2026
Event 5/28/2026
|
||
| RA Capital Management, L.P. | 9.8% | |||
| Peter Kolchinsky | 9.8% | |||
| Rajeev Shah | 9.8% | |||
| RA Capital Healthcare Fund, L.P. | 9.8% | |||
|
Frazier Life Sciences Public Fund, L.P.
13G
|
5.9% |
10/9/2026
Event 10/2/2026
|
||
| Frazier Life Sciences Public Fund, L.P. | 5.9% | |||
| FHMLSP, L.P. | 5.9% | |||
| FHMLSP, L.L.C. | 5.9% | |||
| Frazier Life Sciences XI, L.P. | 0.1% | |||
| FHMLS XI, L.P. | 0.1% | |||
| FHMLS XI, L.L.C. | 0.1% | |||
| Frazier Life Sciences XII, L.P. | 0.4% | |||
| FHMLS XII, L.P. | 0.4% | |||
| FHMLS XII, L.L.C. | 0.4% | |||
|
Opaleye Management Inc.
13G/A
|
5.5% |
7/31/2026
Event 6/30/2026
|
||
| Opaleye Management Inc. | 5.5% | |||
| Opaleye, L.P. | 5.5% | |||
| James Silverman | 5.5% | |||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (7) | ||||
|
Point72 Asset Management, L.P.
13G/A
|
4.95% |
8/14/2026
Event 6/30/2026
|
||
| Point72 Asset Management, L.P. | 4.95% | |||
| Point72 Capital Advisors, Inc. | 4.95% | |||
| Steven A. Cohen | 4.95% | |||
|
Carlyle Group Inc.
13G/A
|
4.1% |
7/6/2026
Event 6/30/2026
|
||
| The Carlyle Group Inc. | 4.1% | |||
| Carlyle Holdings I GP Inc. | 4.1% | |||
| Carlyle Holdings I GP Sub L.L.C. | 4.1% | |||
| Carlyle Holdings I L.P. | 4.1% | |||
| CG Subsidiary Holdings L.L.C. | 4.1% | |||
| TC Group, L.L.C. | 4.1% | |||
| Carlyle Investment Management L.L.C. | 4.1% | |||
| Carlyle Genesis UK LLC | 4.1% | |||
| Abingworth LLP | 4.1% | |||
| Abingworth Bioventures VII LP | 4.1% | |||
|
Atlas Venture Fund X, L.P.
13D/A
|
3.6% |
5/28/2026
Event 5/26/2026
|
||
| Atlas Venture Fund X, L.P. | 3.6% | |||
| Atlas Venture Associates X, L.P. | 3.6% | |||
| Atlas Venture Associates X, LLC | 3.6% | |||
| Atlas Venture Opportunity Fund I, L.P. | 2.1% | |||
| Atlas Venture Associates Opportunity I, L.P. | 2.1% | |||
| Atlas Venture Associates Opportunity I, LLC | 2.1% | |||
| Atlas Venture Opportunity Fund II, L.P. | 3.1% | |||
| Atlas Venture Associates Opportunity II, L.P. | 3.1% | |||
| Atlas Venture Associates Opportunity II, LLC | 3.1% | |||
| Atlas Venture Opportunity Fund Ill, L.P. | 2.6% | |||
| Atlas Venture Associates Opportunity III, L.P. | 2.6% | |||
| Atlas Venture Associates Opportunity III, LLC | 2.6% | |||
| Pfizer Inc 13G/A | 2.3% |
2/13/2026
Event 12/31/2024
|
||
| Bristol Myers Squibb Co 13G/A | 1.6% |
2/14/2025
Event 12/31/2024
|
||
| Sio Capital Management, LLC 13G | 0% |
4/8/2025
Event 3/31/2025
|
||
|
Sirenia Capital Management LP
13G/A
|
0% |
8/14/2026
Event 6/30/2026
|
||
| Sirenia Capital Management LP | 0% | |||
| Alex Silverstein | 0% | |||
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q2 | 74 | 22.2 M | $283 M |
| 2026 Q1 | 53 | 9.43 M | $60.6 M |
| 2025 Q4 | 52 | 8.04 M | $26.7 M |
| 2025 Q3 | 54 | 8.43 M | $16.6 M |
| 2025 Q2 | 64 | 8.99 M | $13.4 M |
| 2025 Q1 | 74 | 9.41 M | $15.5 M |
| 2024 Q4 | 100 | 11.8 M | $40.6 M |
| 2024 Q3 | 75 | 9.11 M | $406 M |
| 2024 Q2 | 58 | 8.07 M | $144 M |
| 2024 Q1 | 43 | 7.43 M | $126 M |